HIV Department, WHO, Geneva, Switzerland.
HIV Department, WHO, Geneva, Switzerland.
Lancet HIV. 2022 Sep;9(9):e658-e666. doi: 10.1016/S2352-3018(22)00101-1. Epub 2022 Jul 18.
Safe and effective paediatric formulations of the most promising antiretroviral drugs are crucial to advance the treatment and prevention of HIV in neonates, infants, children, and adolescents. The WHO Paediatric Drug Optimization for HIV (PADO-HIV) group brings together stakeholders and experts every 2-3 years to identify priority products and define research gaps in the development of new HIV drugs and formulations for children in low-income and middle-income countries. PADO-HIV 5 met from Sept 27 to Oct 15, 2021. The group evaluated HIV agents from known and novel drug classes, oral and parenteral long-acting formulations, and developments in broadly neutralising antibodies, and included focused sessions on neonates and new delivery technologies. A list of medium-term and long-term priorities was generated, and research questions were defined. This forward-looking analysis is intended to provide guidance to funders, drug developers, and researchers, and to accelerate access for children to the best HIV drugs and formulations.
安全有效的儿科抗逆转录病毒药物制剂对于推进新生儿、婴儿、儿童和青少年的艾滋病毒治疗和预防至关重要。世卫组织艾滋病毒儿童药物优化（PADO-HIV）小组每 2-3 年召集利益攸关方和专家，以确定优先产品，并确定在为中低收入国家儿童开发新的艾滋病毒药物和制剂方面的研究空白。PADO-HIV 5 于 2021 年 9 月 27 日至 10 月 15 日举行了会议。该小组评估了来自已知和新型药物类别的抗 HIV 药物、口服和肠外长效制剂，以及广泛中和抗体的发展情况，并包括针对新生儿和新传递技术的重点会议。制定了一份中期和长期优先事项清单，并确定了研究问题。这一前瞻性分析旨在为供资者、药物开发者和研究人员提供指导，加速儿童获得最佳艾滋病毒药物和制剂。
